AI Driven Longevity Economics: Extending Dal Maso's Longevity Capitalism by the No-New-Actor Method, Chained Through the Research Horizon Gap and the Molecular Zero-Day to ALRP, and Stress-Tested Against the 2026 AI Bubble

Four papers already in this corpus establish four separate links. The Asset and the Axiom places Dal Maso's longevity capitalism and this corpus's Biological Zero-Day Mechanism in dialogue and locates a channel — export-controlled frontier AI access — one layer upstream of capital's own mediation. No New Actor To Name shows, using only Erman and Furendal's own market- and epistemic-authority criteria, that OpenAI, Anthropic, and Alphabet are not new entrants to longevity research but the identical actors their AI-governance typology already analyzes, tracked into a second ledger. The Research Horizon Gap shows that the June 2026 export-control actions restricting Fable 5, Mythos 5, and GPT-5.6 create a discovery-velocity asymmetry that operates as a proto-Biological Zero-Day Mechanism independent of price. The Molecular Zero-Day shows, via Nikolas Rose, that this asymmetry's discreteness is not a policy accident but the structural signature of molecular-level intervention as such. ALRP formalizes the resulting instability condition as a ratio, ρ(t) = λ(t)·E[δ]/μ, between a compounding discovery arrival rate and a diffusion capacity this corpus's own hard/soft floor disaggregation has already located precisely. This paper's contribution is not a fifth link. It is the chain itself, stated end to end for the first time, and a stress test neither of the two source conversations that motivated this paper — one arguing an AI bubble mainly touches capital and expectations, the other arguing the corpus's real load-bearing structure sits in BZM and ALRP regardless — fully resolves. Read against Dal Maso's own criterion for what counts as a longevity-capitalism actor, the paper first sharpens the No New Actor finding into a stronger claim: three independently authored frameworks — Erman and Furendal's authority typology, Dal Maso's accumulation-frontier criterion, and this corpus's own BZM/RHG apparatus — converge on the identical three companies without coordination, because in this specific case the actor financializing longevity and the actor accelerating its discovery are not two roles distributed across different firms but one role held by the same three. The paper then runs the actual, current stress test: not whether an AI bubble is real, but what it would touch if it burst. Current market data — the four largest US hyperscalers' 2026 AI capital expenditure now guided toward $725 billion, up 77 percent from 2025, against Sequoia partner David Cahn's own estimate of a $600 billion annual gap between hyperscaler AI spending and actual AI-ecosystem revenue; prediction markets pricing a 2026 bubble collapse at roughly 18 to 21 percent as of this paper's writing, up from 16 percent when the source conversations occurred; and the specific, now substantially larger capital structure of the three named actors — support a finding sharper than either source conversation reached: a funding contraction would not fall evenly across ALRP's ratio. It would fall almost entirely on the diffusion side. Alphabet self-funds Calico and Isomorphic Labs, the latter now backed by $2.7 billion in external capital including sovereign wealth participation; Anthropic's Claude Science sits inside a company whose valuation moved from $183 billion to $965 billion between September 2025 and May 2026 on the strength of a run-rate revenue that itself crossed $47 billion; OpenAI's Retro Biosciences stake traces to a founder's personal capital. None of the three discovery-side actors' longevity programs depends on the speculative equity and venture capital markets a correction would reprice. The diffusion side — manufacturing scale-up, biotech regulatory-affairs staffing, the smaller gene-therapy ventures ALRP's soft floors describe — depends on exactly that capital, and a fourth line of evidence, gathered after the two source conversations and reported here for the first time, shows part of this asymmetry is no longer only a forecast: cell- and gene-therapy financing has been running a documented multi-year slump throughout 2026's broader biotech-financing surge, and early-stage biotech financing generally is on pace for its lowest year of the decade. A correction does not neutralize the paradox. On available evidence, it raises ρ by cutting μ while leaving λ largely intact — and component pieces of that cut are already visible in 2026's own financing data. What a bubble cannot touch at all is RHG's own mechanism, which runs through export-control authority rather than capital markets and is now anchored in a standing federal review framework rather than a single episode, and ALRP's hard floor, which runs through biological time rather than either.